Literature DB >> 30698857

Differential clinical impacts of tumour budding evaluated by the use of immunohistochemical and haematoxylin and eosin staining in stage II colorectal cancer.

Masato Yamadera1, Eiji Shinto1, Yoshiki Kajiwara1, Satsuki Mochizuki1, Koichi Okamoto1, Hideyuki Shimazaki2, Kazuo Hase1, Hideki Ueno1.   

Abstract

AIMS: The aim of this study was to clarify the quantitative and qualitative differences in tumour budding identification between haematoxylin and eosin (H&E) staining and immunohistochemical (IHC) staining for cytokeratin, and to estimate the respective clinical impacts in stage II colorectal cancer. METHODS AND
RESULTS: We retrospectively examined 314 surgically resected cases of stage II colorectal cancer, and assessed tumour budding on serial section slides with H&E staining and IHC staining for cytokeratin. Tumour budding counts based on cytokeratin-stained slides were strongly correlated with those based on H&E-stained slides, and had higher detection and reproducibility. On the basis of receiver operating characteristic analyses, the optimal cut-off values of budding counts for relapse-free survival (RFS) were 7 and 16 in a ×200 microscopic field with H&E and IHC staining, respectively. With these cut-off values, tumour budding based on H&E staining had a significant correlation with RFS (80.3% and 93.2% of 5-year RFS in the high-budding group and the low-budding group, respectively), and similar results were observed for IHC staining (79.9% and 91.7%, respectively). The Akaike Information Criterion value for RFS with H&E staining was favourable as compared with that with IHC staining.
CONCLUSIONS: Tumour budding counts based on cytokeratin-stained slides showed higher detection and better reproducibility, but did not have as satisfactory clinical impacts as those based on H&E staining.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  colorectal carcinoma; cytokeratin; prognostic factors; recurrence; tumour budding

Mesh:

Substances:

Year:  2019        PMID: 30698857     DOI: 10.1111/his.13830

Source DB:  PubMed          Journal:  Histopathology        ISSN: 0309-0167            Impact factor:   5.087


  3 in total

1.  The presence of poorly differentiated clusters predicts survival in stage II colorectal cancer.

Authors:  Serena Ammendola; Giulia Turri; Irene Marconi; Giulia Burato; Sara Pecori; Anna Tomezzoli; Cristian Conti; Corrado Pedrazzani; Valeria Barresi
Journal:  Virchows Arch       Date:  2020-06-23       Impact factor: 4.064

2.  miR‑451 suppresses the malignant characteristics of colorectal cancer via targeting SAMD4B.

Authors:  Chunrong Wu; Xiaohu Liu; Bo Li; Guiying Sun; Chunfang Peng; Debing Xiang
Journal:  Mol Med Rep       Date:  2021-06-10       Impact factor: 2.952

3.  Immunohistochemical-based molecular subtyping of colorectal carcinoma using maspin and markers of epithelial-mesenchymal transition.

Authors:  Laura Banias; Ioan Jung; Tivadar Bara; Zsolt Fulop; Patricia Simu; Iunius Simu; Catalin Satala; Simona Gurzu
Journal:  Oncol Lett       Date:  2019-12-18       Impact factor: 2.967

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.